JPWO2019217924A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019217924A5 JPWO2019217924A5 JP2020562201A JP2020562201A JPWO2019217924A5 JP WO2019217924 A5 JPWO2019217924 A5 JP WO2019217924A5 JP 2020562201 A JP2020562201 A JP 2020562201A JP 2020562201 A JP2020562201 A JP 2020562201A JP WO2019217924 A5 JPWO2019217924 A5 JP WO2019217924A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- oral administration
- human
- use according
- max
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 58
- 102000004257 Potassium Channel Human genes 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 108020001213 potassium channel Proteins 0.000 claims 3
- 206010001497 Agitation Diseases 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 1
- 108010006746 KCNQ2 Potassium Channel Proteins 0.000 claims 1
- 102000005453 KCNQ2 Potassium Channel Human genes 0.000 claims 1
- 108010038888 KCNQ3 Potassium Channel Proteins 0.000 claims 1
- 102000015686 KCNQ3 Potassium Channel Human genes 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 230000002594 corticospinal effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- FJNPZKZPWVVSON-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 FJNPZKZPWVVSON-UHFFFAOYSA-N 0.000 claims 1
- 230000001314 paroxysmal effect Effects 0.000 claims 1
- 230000036470 plasma concentration Effects 0.000 claims 1
- 230000000291 postprandial effect Effects 0.000 claims 1
- 230000000284 resting effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862670253P | 2018-05-11 | 2018-05-11 | |
| US62/670,253 | 2018-05-11 | ||
| PCT/US2019/031872 WO2019217924A1 (en) | 2018-05-11 | 2019-05-10 | Methods for enhancing the bioavailability and exposure of a voltage-gated potassium channel opener |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523130A JP2021523130A (ja) | 2021-09-02 |
| JPWO2019217924A5 true JPWO2019217924A5 (es) | 2022-05-17 |
| JP7570924B2 JP7570924B2 (ja) | 2024-10-22 |
Family
ID=66669101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020562201A Active JP7570924B2 (ja) | 2018-05-11 | 2019-05-10 | 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法 |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US11135214B2 (es) |
| EP (2) | EP4279133A3 (es) |
| JP (1) | JP7570924B2 (es) |
| KR (1) | KR20210020892A (es) |
| CN (1) | CN112384216A (es) |
| AU (2) | AU2019265002B2 (es) |
| BR (1) | BR112020022713A2 (es) |
| CA (1) | CA3099292A1 (es) |
| CL (1) | CL2020002932A1 (es) |
| CO (1) | CO2020015476A2 (es) |
| CR (1) | CR20200602A (es) |
| DK (1) | DK3790548T3 (es) |
| EA (1) | EA202092720A1 (es) |
| ES (1) | ES2964409T3 (es) |
| FI (1) | FI3790548T3 (es) |
| GE (1) | GEP20237527B (es) |
| HR (1) | HRP20231447T1 (es) |
| HU (1) | HUE064326T2 (es) |
| LT (1) | LT3790548T (es) |
| MA (1) | MA52569B1 (es) |
| MD (1) | MD3790548T2 (es) |
| MX (2) | MX2020012008A (es) |
| PE (1) | PE20211211A1 (es) |
| PH (1) | PH12020551898A1 (es) |
| PL (1) | PL3790548T3 (es) |
| PT (1) | PT3790548T (es) |
| RS (1) | RS64922B1 (es) |
| SG (1) | SG11202011102TA (es) |
| SI (1) | SI3790548T1 (es) |
| UA (1) | UA127229C2 (es) |
| WO (1) | WO2019217924A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS64922B1 (sr) | 2018-05-11 | 2023-12-29 | Xenon Pharmaceuticals Inc | Postupci za povećanje bioraspoloživosti i izloženosti otvaraču naponom kontrolisanih kalijumskih kanala |
| TW202128627A (zh) | 2019-10-10 | 2021-08-01 | 加拿大商再諾製藥公司 | 選擇性鉀通道調節劑之固態晶型 |
| IL293504A (en) * | 2019-12-06 | 2022-08-01 | Xenon Pharmaceuticals Inc | Using kv7 potassium channel opener for pain treatment |
| US20220288057A1 (en) * | 2021-02-09 | 2022-09-15 | Xenon Pharmaceuticals Inc. | Conjoint therapy for treating seizure disorders |
| CN116847843A (zh) * | 2021-02-09 | 2023-10-03 | 泽农医药公司 | 用于治疗快感缺乏的电压门控的钾通道开放剂 |
| CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
| JP7294734B2 (ja) * | 2021-10-27 | 2023-06-20 | シャンハイ ジムン バイオファーマ，インコーポレーテッド | カリウムチャネル調節剤としての化合物ならびにその調製および応用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8236861B2 (en) | 2004-02-13 | 2012-08-07 | Hormos Medical Corporation | Method for enhancing the bioavailablity of ospemifene |
| EP1891089B1 (en) | 2005-06-02 | 2014-11-05 | Merck Sharp & Dohme Corp. | HCV protease inhibitors in combination with food |
| JP2009535370A (ja) | 2006-05-02 | 2009-10-01 | クリス ルントフェルト | ジストニアおよびジストニア様症状の予防および治療におけるカリウムチャンネル活性剤 |
| DK2061465T3 (da) * | 2006-08-23 | 2013-07-08 | Valeant Pharmaceuticals Int | Derivater af 4-(N-azacycloalkyl)anilider som kaliumkanalmodulatorer |
| US8993593B2 (en) | 2006-08-23 | 2015-03-31 | Valeant Pharmaceuticals International | N-(4-(6-fluoro-3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3-dimethylbutanamide as potassium channel modulators |
| US20100323016A1 (en) * | 2008-07-18 | 2010-12-23 | Biljana Nadjsombati | Modified release formulation and methods of use |
| MX2012008413A (es) * | 2010-01-20 | 2012-08-15 | Glaxo Group Ltd | Composicion novedosa de retigabina. |
| US10500216B2 (en) | 2011-11-18 | 2019-12-10 | Corcept Therapeutics, Inc. | Optimizing mifepristone absorption |
| RS64922B1 (sr) | 2018-05-11 | 2023-12-29 | Xenon Pharmaceuticals Inc | Postupci za povećanje bioraspoloživosti i izloženosti otvaraču naponom kontrolisanih kalijumskih kanala |
-
2019
- 2019-05-10 RS RS20231089A patent/RS64922B1/sr unknown
- 2019-05-10 EP EP23185386.2A patent/EP4279133A3/en active Pending
- 2019-05-10 EP EP19727216.4A patent/EP3790548B1/en active Active
- 2019-05-10 HU HUE19727216A patent/HUE064326T2/hu unknown
- 2019-05-10 PE PE2020001843A patent/PE20211211A1/es unknown
- 2019-05-10 CR CR20200602A patent/CR20200602A/es unknown
- 2019-05-10 FI FIEP19727216.4T patent/FI3790548T3/fi active
- 2019-05-10 AU AU2019265002A patent/AU2019265002B2/en active Active
- 2019-05-10 SG SG11202011102TA patent/SG11202011102TA/en unknown
- 2019-05-10 MD MDE20210233T patent/MD3790548T2/ro unknown
- 2019-05-10 EA EA202092720A patent/EA202092720A1/ru unknown
- 2019-05-10 CA CA3099292A patent/CA3099292A1/en active Pending
- 2019-05-10 SI SI201930665T patent/SI3790548T1/sl unknown
- 2019-05-10 JP JP2020562201A patent/JP7570924B2/ja active Active
- 2019-05-10 UA UAA202007781A patent/UA127229C2/uk unknown
- 2019-05-10 KR KR1020207035334A patent/KR20210020892A/ko unknown
- 2019-05-10 MA MA52569A patent/MA52569B1/fr unknown
- 2019-05-10 CN CN201980046273.0A patent/CN112384216A/zh active Pending
- 2019-05-10 MX MX2020012008A patent/MX2020012008A/es unknown
- 2019-05-10 GE GEAP201915508A patent/GEP20237527B/en unknown
- 2019-05-10 LT LTEPPCT/US2019/031872T patent/LT3790548T/lt unknown
- 2019-05-10 DK DK19727216.4T patent/DK3790548T3/da active
- 2019-05-10 BR BR112020022713-7A patent/BR112020022713A2/pt unknown
- 2019-05-10 PL PL19727216.4T patent/PL3790548T3/pl unknown
- 2019-05-10 HR HRP20231447TT patent/HRP20231447T1/hr unknown
- 2019-05-10 WO PCT/US2019/031872 patent/WO2019217924A1/en active Application Filing
- 2019-05-10 PT PT197272164T patent/PT3790548T/pt unknown
- 2019-05-10 ES ES19727216T patent/ES2964409T3/es active Active
- 2019-05-13 US US16/410,851 patent/US11135214B2/en active Active
-
2020
- 2020-11-09 PH PH12020551898A patent/PH12020551898A1/en unknown
- 2020-11-10 MX MX2023013247A patent/MX2023013247A/es unknown
- 2020-11-11 CL CL2020002932A patent/CL2020002932A1/es unknown
- 2020-12-11 CO CONC2020/0015476A patent/CO2020015476A2/es unknown
-
2021
- 2021-10-01 US US17/449,785 patent/US20220062266A1/en active Pending
-
2024
- 2024-04-26 US US18/648,049 patent/US20240316032A1/en active Pending
- 2024-05-30 US US18/679,045 patent/US20240316033A1/en active Pending
- 2024-09-17 AU AU2024219794A patent/AU2024219794A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210378972A1 (en) | Low dose topiramate/phentermine composition and methods of use thereof | |
| EP2317997B1 (en) | Low dose topiramate/phentermine compostion and methods of use thereof | |
| JP2024069192A5 (es) | ||
| JP7570924B2 (ja) | 電位依存性カリウムチャネル開口薬のバイオアベイラビリティー及び曝露を高める方法 | |
| WO2010107404A1 (en) | Stable pharmaceutical combinations | |
| CN101208097A (zh) | 用于治疗痤疮的方法 | |
| JPWO2019217924A5 (es) | ||
| US8529879B2 (en) | Epithelium-improving agent | |
| WO2005034936A1 (fr) | Utilisation de l-butylphtalide dans la fabrication de medicaments destines a la prevention et au traitement de l'infarctus cerebral | |
| SK111894A3 (en) | Pharmaceutical agents for treatment of granulomatese and fibrously pulmonary illnesess | |
| US20060251731A1 (en) | Therapeutic herbal lozenge composition | |
| JP2001518481A (ja) | 経口投与のためのセロトニン含有製剤及びその使用方法 | |
| WO2004058244A1 (fr) | Utilisation d'esters de derives succinate pour le traitement de la demence | |
| EP1498119B1 (en) | Use of conjugated linoleic acid for treating colds | |
| WO2021173707A1 (en) | Compositions and methods for treatment of cytokine storm and cytokine release syndrome | |
| JPWO2019232130A5 (es) | ||
| FR2683722A1 (fr) | Medicament pour le traitement de fond de l'asthme a base de beta-carotene. | |
| JPWO2021097038A5 (es) | ||
| JPWO2020123824A5 (es) | ||
| EP4415733A1 (fr) | Combinaison d'e. faecalis et d'un agent anti-inflammatoire et ses utilisations dans la prevention et/ou traitement des maladies respiratoires | |
| AU2016203698B2 (en) | Low Dose Topiramate/Phentermine Composition and Methods of Use Thereof | |
| EP1275638A1 (de) | Kombinationspräparat zur Therapie von immunologischen Erkrankungen | |
| BE829197A (fr) | Compositions anti-inflammatoires, leur preparation et leur utilisation | |
| EP3763365A1 (en) | Aroylimidazolones for the treatment of thaumetopoea exposure | |
| EA021199B1 (ru) | Способ терапевтического или профилактического лечения невропатической боли, хронической боли и фибромиалгии |